Superbug fight unites drug industry

More than 80 international drug and biotech firms urged governments to work with them to combat drug-resistant superbugs which could kill tens of millions of people within decades unless progress is made and new antibiotics found.

Britain's chief medical officer Sally Davies applauds industry commitment to beat antimicrobial resistance

A surgery nurse prepares a syringe during procedures to clean the wound of an amputee patient with MRSA (Methicillin resistant Staphylococcus Aureus) superbug in Berlin. (Fabrizio Bensch/Reuters)
  More than 80 international drug and biotech firms urged governments to work with them to combat drug-resistant superbugs which could kill tens of millions of people within decades unless progress is made and new antibiotics found.

In a declaration at the World Economic Forum in Davos, they called for coordinated efforts to cut unnecessary use of antibiotics and support development of new ones, including through changing drug prices and investing in research.

  The 83 pharmaceutical companies and eight industry groups urged governments around the world to commit money "to provide appropriate incentives …for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development."

Any use of antibiotics promotes the development and spread of so-called superbugs — multi-drug-resistant infections that can evade the medicines designed to kill them. International alarm about the superbug threat is rising after the discovery in China of a gene called mcr-1 that makes bacteria resistant to all known antibiotics. 

  "For the world to continue to have new antibiotics, we need investments in basic science and novel incentive models for industry R&D, and to protect our existing treatments, we need new frameworks for appropriate use," said Paul Stoffels, chief scientific officer of Johnson & Johnson.

Former Goldman Sachs chief economist Jim O'Neill was asked in 2014 by Britain's prime minister to conduct a full review of the problem and suggest ways to combat it.

In his initial report, he estimated antibiotic and microbial resistance could kill an extra 10 million people a year and cost up to $100 trillion US by 2050 if it is not brought under control.

  While the problem of infectious bugs becoming drug-resistant has been a feature of medicine since the discovery of the first antibiotic, penicillin, in 1928, it has grown in recent years as drugmakers have cut back investment in the field.

The Declaration on Combating Antimicrobial Resistance calls for steps including:

  • Governments committing funding to implement the World Health Organization's Global Action Plan to create programs ensuring that health systems use antibiotics appropriately, along with increasing use of fast diagnostic tests and boosting reimbursements for them to ensure patients get the correct treatment.
  • Better education of doctors and nurses on appropriate antibioticuse.
  • Improved infection control through better hygiene, vaccination and preventive treatments.
  • Reduced used of antibiotics in livestock.
  • Higher reimbursements for antibiotics and diagnostic tests in developed markets.
  • More collaboration between researchers at drugmakers and those at universities and government.
  • More access to antibiotics in countries around the world.

Britain's chief medical officer Sally Davies said the declaration was "a clear sign of industry's collective commitment to beating the threat of antimicrobial resistance."

  "I look forward to seeing an advancement of discussions between companies and governments on how we build new and sustainable market models that properly incentivize the discovery and development of new antibiotics, whilst ensuring affordable access to these crucial drugs for all," she said. 

With files from Associated Press


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?